Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 5, 2015, Pages 941-944

  Bradstock, Kenneth F ^a   Bilmon, Ian ^a   Kwan, John ^a   Micklethwaite, Kenneth ^a   Blyth, Emily ^a   Deren, Stephanie ^a   Bayley, Angela ^a   Gebski, Val ^b   Gottlieb, David ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Allogeneic; Bone marrow transplantation; Cyclophosphamide; Graft versus host disease; Peripheral blood stem cells; Prophylaxis

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; MELPHALAN; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATALITY; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; ACUTE DISEASE; CLINICAL TRIAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; AGED; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION CONDITIONING;

EID: 84928168619     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.01.020     Document Type: Article

References (24)

1. Holtan S.G., Pasquini M., Weisdorf D.J. Acute graft-versus-host disease: a bench to bedside update. Blood 2014, 124:363-373.
2. Luznik L., Bolanos-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115:3224-3230.
3. Luznik L., Fuchs E.J. High dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 2010, 47:65-77.
4. Jones R.J., Barber J.P., Vala M.S., et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995, 85:2742-2746.
5. Kanakry C.G., Ganguly S., Zahurak M., et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Science Trans Med 2013, 5:211ra157.
6. Kanakry C.G., Tsai H.-L., Balanos-Mead J., et al. Post-transplant cyclophosphamide as single agent GVHD prophylaxis after myeloablative conditioning and HLA-matched allografting for acute leukemias and myelodysplastic syndrome. Blood 2014, 124:3817-3827.
7. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
8. Kanakry C.G., O'Donnell P.V., Furlong T., et al. Multi-institutional study of post-transplant cyclophosphamide as single agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. JClin Oncol 2014, 32:3497-3505.
9. Allogeneic peripheral blood stem cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. JClin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
10. Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft versus host disease without improved survival. Biol Blood Marrow Transplant 2007, 13:1461-1468.
11. Jagasia M., Arora M., Flowers M.E.D., et al. Risk factors for acute and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
12. Anasetti C., Logan B.R., Lee S.J., et al. Peripheral blood stem cells versus bone marrow from unrelated donors. New Eng J Med 2012, 367:1487-1496.
13. Raj K., Pagliuca A., Bradstock K.F., et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014, 20:890-895.
14. Castagna L., Crocchiolo R., Furst S., et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a non-myeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014, 20:724-729.
15. Solomon S.R., Sizemore C.A., Sanacore M., et al. Haploidentical transplantation using T cell-replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012, 18:1859-1866.
16. Bashey A., Zhang X., Sizemore C.A., et al. Tcell-replete haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. JClin Oncol 2013, 31:1310-1316.
17. Marks R., Potthoff K., Hahn J., et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008, 112:415-425.
18. Slack J.L., Dueck A.C., Fauable V.D., et al. Reduced toxicity conditioning and allogeneic Stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. Biol Blood Marrow Transplant 2013, 19:1167-1174.
19. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
20. Mehta C.R., Cain K.C. Charts for the early stopping of clinical studies. JClin Oncol 1984, 2:676-682.
21. Miecarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
22. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA-identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the acute leukaemia working party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
23. Hahn T., McCarthy P.L., Zhang M.-J., et al. Risk factors for acute graft-versus-host disease after human leukocyte-identical sibling transplants for adults with leukemia. JClin Oncol 2008, 26:5728-5734.
24. Solomon S.R., Sanacore M., Zhang X., et al. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief course sirolimus following reduced intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:1828-1834.